ExcellGene

Executive Summary

ExcellGene SA is a Swiss contract development and manufacturing organization (CDMO) that has established itself as a specialized partner in mammalian cell culture for biopharmaceutical production. Founded in 1998 and headquartered in Monthey, the company offers end-to-end services from cell line development to GMP manufacturing, focusing on monoclonal antibodies, biosimilars, and viral vectors. By leveraging proprietary expression technologies, ExcellGene enables accelerated timelines and high yields for its clients, positioning itself as a key player in the growing outsourced biomanufacturing market. The company’s long-standing presence and technical expertise provide a strong foundation for capturing demand from both large pharma and emerging biotechs. Recent strategic investments in capacity expansion and process development reflect ExcellGene’s commitment to meeting surging demand for viral vectors and complex biologics. With the CDMO market expected to grow steadily, the company is well-placed to benefit from trends such as biosimilar adoption and gene therapy advancements. Despite being privately held, ExcellGene’s robust service portfolio and client partnerships suggest a promising trajectory. Continued focus on innovation and operational excellence will be key to maintaining its competitive edge in the fragmented global CDMO landscape.

Upcoming Catalysts (preview)

• Q2 2026Major multi-year contract with top-20 pharma for mAb production60% success
• Q4 2026Completion of GMP-certified viral vector manufacturing suite75% success
• Q1 2027Launch of next-generation CHO expression platform50% success